REVIEW PAPER
COVID-19 humoral response
1
Clinical Department of Internal Medicine and Gastroenterology with Inflammatory Bowel Disease Unit, Central Clinical Hospital of the Ministry of the Interior and Administration, Warsaw, Poland
2
Department of Internal Medicine, Nephrology and Transplantation Medicine, Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw, Poland
3
Centre of Postgraduate Medical Education, Warsaw, Poland
4
Collegium Medicum, Jan Kochanowski University, Kielce, Poland
Submission date: 2023-04-27
Final revision date: 2023-06-25
Acceptance date: 2023-06-27
Publication date: 2023-09-30
Corresponding author
Adam Tworek
Adam Tworek Clinical Department of Internal Medicine and Gastroenterology with Inflammatory Bowel Disease Unit Central Clinical Hospital of the Ministry of the Interior and Administration 137 Wołoska St, 02-507 Warsaw, Poland
Adam Tworek Clinical Department of Internal Medicine and Gastroenterology with Inflammatory Bowel Disease Unit Central Clinical Hospital of the Ministry of the Interior and Administration 137 Wołoska St, 02-507 Warsaw, Poland
Medical Studies 2023;39(3):296-303
KEYWORDS
TOPICS
ABSTRACT
This article reviews studies on SARS-CoV-2 antibodies, including neutralizing antibodies (NAbs) and post-vaccination response. The SARS-CoV-2 virus is closely related to SARS-CoV and MERS-CoV, sharing 79% and 50% of its genome sequence with them, respectively. Antibodies are crucial in identifying and destroying pathogens such as viruses, and understanding virus-specific antibodies can help end pandemics quickly. The SARS-CoV-2 virus uses the spike protein to enter human cells via the angiotensin-converting enzyme 2 receptor (ACE2). The immune response to the virus involves various components, including dendritic cells, T cells, B cells, and NAbs. Seroconversion, antibody kinetics, and immune response after COVID-19 vaccination are essential factors in understanding the virus and developing treatments. Neutralizing antibody therapies have been explored as potential treatments, but the emergence of viral variants challenges their long-term development. Lessons learned from antibody-based therapies can influence future strategies for treating emerging infectious diseases.
REFERENCES (58)
1.
Pekar J, Zhang Y, Gearing M, Pan M, Yan H, Zhang S, Wang G, Chen X, Chen L, Chen Z, Zhu H. Timing the SARS-CoV-2 index case in Hubei Province. Science 2021; 372: 412-417.
2.
Brant AC, Simões E Silva AC, Souza JP, Abreu BJ, Duar- te AJ, Oliveira SC. SARS-CoV-2: from its discovery to genome structure, transcription, and replication. Cell Biosci 2021; 11: 211.
3.
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395: 565-574.
4.
Woof JM, Burton DR. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol 2004; 4: 89-99.
5.
Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A, Li F. Structural basis of receptor recognition by SARS-CoV-2. Nature 2020; 581: 221-224.
6.
Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L, Wang X. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020; 581: 215-220.
7.
Shaik MM, Peng H, Lu J, Rits-Volloch S, Xu C, Liao M, Chen B. Structural basis of coreceptor recognition by HIV-1 envelope spike. Nature 2019; 565: 318-323.
8.
Jangra S, De Vrieze J, Choi A, Rathnasinghe R, Laghlali G, Uvyn A, Van Herck S, Ozorowski G, De Waele J, Sche- pens W, Roose K. Sterilizing immunity against SARS-CoV-2 infection in mice by a single-shot and lipid amphiphile imidazoquinoline TLR7/8 agonist-adjuvanted recombinant spike protein vaccine. Angew Chem Int 2021; 60: 9467-9473.
9.
Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, Wang YY, Xiao GF, Yan B, Shi ZL, Zhou P. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. J Med Virol 2020; 92: 1691-1697.
10.
Sun B, Feng Y, Mo X, Zheng P, Wang Q, Li P, Peng P, Liu X, Chen Z, Huang H, Zhang F, Luo W, Niu X, Hu P, Wang L, Peng H, Huang Z, Feng L, Li F, Zhang F, Li F, Zhong N, Chen L. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect 2020; 9: 940-948.
11.
Shrock E, Fujimura E, Kula T, Timms RT, Lee IH, Leng Y, Robinson ML, Sie BM, Li MZ, Chen Y, Logue J, Zuiani A, McCulloch D, Lelis FJN, Henson S, Monaco D, Tra- vers M, Habibi S, Clarke WA, Caturegli P, Laeyendecker O, Piechocka-Trocha A, Li JZ, Khatri A, Chu HY; MGH COVID-19 Collection & Processing Team; Villani AC, Kays K, Goldberg MB, Hacohen N, Filbin MR, Yu XG, Walker BD, Wesemann DR, Larman HB, Lederer JA, Elledge SJ. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science 2020; 370: 4250.
12.
Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID-19. Nat Rev Immunol 2020; 20: 339-341.
13.
Wang SF, Tseng SP, Yen CH, Yang JY, Tsao CH, Shen CW, Chen KH, Liu FT, Liu WT, Chen YMA, Huang JC. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem Biophys Res Commun 2014; 451: 208-214.
14.
Rijkers G, Murk JL, Wintermans B, van Looy B, van den Berge M, Veenemans J, Stohr J, Reusken C, van der Pol P, Reimerink J. Differences in antibody kinetics and functionality between severe and mild SARS-CoV-2 infections. J Infect Dis 2020; 222: 1265-1269.
15.
Ren L, Zhang R, Chang D, Wang J, Hu Y, Chen H, Guo L, Wu C, Wang C, Wang Y, Wang Y, Wang G, Yang S, Dela Cruz CS, Sharma L, Wang L, Zhang D, Wang J. The kinetics of humoral response and its relationship with the disease severity in COVID-19. Commun Biol 2020; 3: 780.
16.
Yadav AK, Ghosh S, Kotwal A, Kaushik SK, Bobdey S, Sahu R, Kapoor S, Faujdar DS, Teli PT, Anand V. Seroconversion among COVID-19 patients admitted in a dedicated COVID hospital: a longitudinal prospective study of 1000 patients. Med J Armed Forces India 2021; 77 (Suppl 1): S379-S384.
17.
Zhang B, Yue D, Wang Y, Wang F, Wu S, Hou H. The dynamics of immune response in COVID-19 patients with different illness severity. J Med Virol 2021; 93: 1070-1077.
18.
Agarwal A, Baghmar S, Qureshi S, Khurana A, Setia R, Khan MA, Barman P, Kapoor RK, Hasthavaram NR, Kumar R, Singh N, Sarin A, Handoo A. Persistent antibody responses to SARS-CoV-2 infection in cancer patients: a single-center retrospective observational study. Indian J Med Paediatr Oncol 2021; 42: 123-129.
19.
Hedges JF, Thompson MA, Snyder DT, Robison A, Tay- lor MP, Jutila MA. Titers, prevalence, and duration of Sars-Cov-2 antibodies in a local Covid-19 Outbreak and following vaccination. Vaccines 2021; 9: 587.
20.
Achiron A, Gurevich M, Falb R, Dreyer-Alster S, Sonis P, Mandel M. SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects. Clin Microbiol Infect 2021; 27: 1349.e1-1349.e6.
21.
Garcia-Beltran WF, Lam EC, Astudillo MG, Yang D, Mil- ler TE, Feldman J, Hauser BM, Caradonna TM, Clayton KL, Nitido AD, Murali MR, Alter G, Charles RC, Dighe A, Bran- da JA, Lennerz JK, Lingwood D, Schmidt AG, Iafrate AJ, Balazs AB. COVID-19-neutralizing antibodies predict disease severity and survival. Cell 2021; 184: 476-488.e11.
22.
Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 2021; 184: 861-880.
23.
Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, Ulferts R, Earl C, Wrobel AG, Benton DJ, Rou- stan C, Bolland W, Thompson R, Agua-Doce A, Hobson P, Heaney J, Rickman H, Paraskevopoulou S, Houlihan CF, Thomson K, Sanchez E, Shin GY, Spyer MJ, Joshi D, O’Reilly N, Walker PA, Kjaer S, Riddell A, Moore C, Jebson BR, Wilkinson M, Marshall LR, Rosser EC, Radziszewska A, Peckham H, Ciurtin C, Wedderburn LR, Beale R, Swanton C, Gandhi S, Stockinger B, McCauley J, Gamblin SJ, McCoy LE, Cherepanov P, Nastouli E, Kassiotis G. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science 2020; 370: 1339-1343.
24.
Nguyen-Contant P, Embong AK, Kanagaiah P, Chaves FA, Yang H, Branche AR, Topham DJ, Sangster MY. S Protein-reactive IGG and memory B cell production after human SARS-CoV-2 infection includes broad reactivity to the S2 subunit. mBio 2020; 11: e01991-20.
25.
Varona JF, Madurga R, Peñalver F, Abarca E, Almirall C, Cruz M, Ramos E, Castellano-Vazquez JM. Kinetics of anti-SARS-CoV-2 antibodies over time. Results of 10 month follow up in over 300 seropositive health care workers. Eur J Intern Med 2021; 89: 97-103.
26.
Liu G, Rusling JF. COVID-19 antibody tests and their limitations. ACS Sens 2021; 6: 593-612.
27.
Hicks J, Klumpp-Thomas C, Kalish H, Shunmugavel A, Mehalko J, Denson JP, Snead KR, Drew M, Corbett KS, Graham BS, Hall MD, Memoli MJ, Esposito D, Sadtler K. Serologic cross-reactivity of SARS-CoV-2 with endemic and seasonal betacoronaviruses. J Clin Immunol 2021; 41: 906-913.
28.
Lv H, Wu N, Tsang OTY, Yuan M, Perera RAPM, Leung WS, So RTY, Chan JMC, Yip GK, Chik TSH, Wang Y, Choi CYC, Lin Y, Ng WW, Zhao J, Poon LLM, Peiris JSM, Wilson IA, Mok CKP. Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections. Cell Rep 2020; 31: 107725.
29.
Al-Alawi S, Al-Hinai H, Al-Kindi N, Al-Rashidi M, Al-Kindi H, Al-Shukri I, Al-Rashdi A, Jose S, Al-Jardani A. Evaluation of four rapid antigen tests for detection of SARS-CoV-2 virus. Oman Med J 2021; 36: e273.
30.
Hsieh WY, Lin CH, Lin TC, Lin CH, Chang HF, Tsai CH, Wu HT, Lin CS. Development and efficacy of lateral flow point-of-care testing devices for rapid and mass COVID-19 diagnosis by the detections of SARS-CoV-2 antigen and anti-SARS-CoV-2 antibodies. Diagnostics 2021; 11: 1760.
31.
Kopel J, Goyal H, Perisetti A. Antibody tests for COVID-19. Proc Bayl Univ Med Cent 2021; 34: 63-72.
32.
Mouliou DS, Gourgoulianis KI. False-positive and false-negative COVID-19 cases: respiratory prevention and management strategies, vaccination, and further perspectives. Expert Rev Respir Med 2021; 15: 993-1002.
33.
Jalkanen P, Kolehmainen P, Häkkinen HK, Huttunen M, Tähtinen PA, Lundberg R, Maljanen S, Reinholm A, Tauriainen S, Pakkanen SH, Levonen I, Nousiainen A, Miller T, Välimaa H, Ivaska L, Pasternack A, Naves R, Ritvos O, Österlund P, Kuivanen S, Smura T, Hepojoki J, Vapalahti O, Lempainen J, Kakkola L, Kantele A, Julkunen I. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nat Commun 2021; 12: 3991.
34.
Martínez-Baz I, Miqueleiz A, Casado I, Navascués A, Trobajo-Sanmartín C, Burgui C, Guevara M, Ezpeleta C, Castilla J; Working Group for the Study of COVID-19 in Navarra. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021. Euro Surveill 2021; 26: 2100438.
35.
Ibarrondo FJ, Hofmann C, Fulcher JA, Goodman-Meza D, Mu W, Hausner MA, Ali A, Balamurugan A, Taus E, Elliott J, Krogstad P, Tobin NH, Ferbas KG, Kitchen SG, Aldrovandi GM, Rimoin AW, Yang OO. Primary, recall, and decay kinetics of SARS-CoV-2 vaccine antibody responses. ACS Nano 2021; 15: 11180-11191.
36.
Tada T, Zhou H, Dcosta BM, Samanovic MI, Dcosta BM, Cornelius A, Mulligan MJ, Landau NR. Comparison of neutralizing antibody titers elicited by mRNA and adenoviral vector vaccine against SARS-CoV-2 variants. bioRxiv 2021: 2021.07.19.452771.
37.
Nordström P, Ballin M, Nordström A. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic COVID-19 infection in Sweden: a nationwide cohort study. Lancet Reg Health Eur 2021; 11: 100249.
38.
Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Ramos GM, Dopfer-Jablonka A, Heidemann A, Ritter C, Friedrichsen M, Schultze-Florey C, Ravens I, Willenzon S, Bubke A, Ristenpart J, Janssen A, Ssebyatika G, Bernhardt G, Münch J, Hoffmann M, Pöhlmann S, Krey T, Bošnjak B, Förster R, Behrens GMN. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 NCoV-19/BNT162b2 vaccination. Nat Med 2021; 27: 1525-1529.
39.
Muik A, Lui BG, Wallisch AK, Bacher M, Mühl J, Reinholz J, Ozhelvaci O, Beckmann N, de la Caridad Güimil Gar- cia R, Poran A, Shpyro S, Finlayson A, Cai H, Yang Q, Swan- son KA, Türeci Ö, Şahin U. Neutralization of SARS-CoV-2 omicron by BNT162b2 mRNA vaccine-elicited human sera. Science 2022; 375: 678-680.
40.
Khoury DS, Cromer D, Reynaldi A, Schlub TE, Whea- tley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021; 27: 1205-1211.
41.
Modenese A, Paduano S, Bellucci R, Marchetti S, Bruno F, Grazioli P, Vivoli R, Gobba F, Bargellini A. Investigation of possible factors influencing the neutralizing anti-SARS-CoV-2 antibody titer after six months from the second vaccination dose in a sample of italian nursing home personnel. Antibodies (Basel) 2022; 11: 59.
42.
Hurt AC, Wheatley AK. Neutralizing antibody therapeutics for Covid-19. Viruses 2021; 13: 628.
43.
Platzer B, Stout M, Fiebiger E. Antigen cross-presentation of immune complexes. Front Immunol 2014; 5: 140.
44.
Mueller AL, McNamara MS, Sinclair DA. Why does COVID-19 disproportionately affect older people? Aging (Albany NY) 2020; 12: 9959-9981.
45.
Fung M, Babik JM. COVID-19 in immunocompromised hosts: what we know so far. Clin Infect Dis 2021; 72: 340-350.
46.
COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. Nature 2021; 600: 472-477.
47.
Jayawardena R, Sooriyaarachchi P, Chourdakis M, Jeewandara C, Ranasinghe P. Enhancing immunity in viral infections, with special emphasis on COVID-19: a review. Diabetes Metab Syndr 2020; 14: 367-382.
48.
Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald HI, MacKenna B, Tomlinson L, Douglas IJ, Rentsch CT, Mathur R, Wong AYS, Grieve R, Harrison D, Forbes H, Schultze A, Croker R, Parry J, He- ster F, Harper S, Perera R, Evans SJW, Smeeth L, Goldacre B. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020; 584: 430-436.
49.
Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, Bermúdez-González MC, Bie- lak DA, Carreño JM, Chernet RL, Eaker LQ, Ferreri ED, Floda D, Gleason CR, Hamburger JZ, Jiang K, Kleiner G, Jurczyszak D, Matthews JC, Mendez WA, Nabeel I, Mulder LCF, Raskin AJ, Russo Kayla T, Salimbangon ABT, Saksena M, Shin AS, Singh G, Sominsky LA, Stadlbauer D, Wajnberg A, Simon V. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med 2021; 384: 1372-1374.
50.
BMJ. COVID-19: The BMJ’s Coronavirus Hub [Internet]. BMJ. [cited 2023 Apr 25]. https://www.bmj.com/content/38....
51.
MAGICapp. National COVID-19 Clinical Evidence Taskforce [Internet]. Australian Government Department of Health. [cited 2023 Apr 25]. https://app.magicapp.org/#/gui....
52.
Zhou P, Song G, Liu H, Yuan M, He WT, Beutler N, Zhu X, Tse LV, Martinez D, Schäfer A, Anzanello F, Yong P, Peng L, Dueker K, Musharrafieh R, Callaghan S, Capozzola T, Limbo O, Parren M, Garcia E, Rawlings SA, Smith DM, Nemazee D, Jardine JG, Safonova Y, Briney B, Rogers TF, Wilson IA, Baric RS, Gralinski LE, Burton DR, Andrabi R. Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease. Immunity 2023; 56: 669-686.
53.
Kim DM, Kim HS, Seo JW, Lee J, Park U, Ha NY, Koh J, Park H, Lee JW, Ro HJ, Yun NR, Kim DY, Yoon SH, Na YS, Moon DS, Lim SC, Kim CM, Jeon K, Kang JG, Jang NY, Jeong H, Kim J, Cheon S, Sohn KM, Moon JY, Kym S, Han SR, Lee MS, Kim HJ, Park WY, Choi JY, Shin HW, Kim HY, Cho CH, Jeon YK, Kim YS, Cho NH. Enhanced eosinophil-mediated inflammation associated with antibody and complement-dependent pneumonic insults in critical COVID-19. Cell Rep 2021; 37: 109798.
54.
Ankerhold J, Giese S, Kolb P, Maul-Pavicic A, Voll RE, Göppert N, Ciminski K, Kreutz C, Lother A, Salzer U, Bildl W, Welsink T Morgenthaler NG, Grawitz AB, Huzly D, Schwemmle M, Hengel H, Falcone V. Circulating multimeric immune complexes drive immunopathology in COVID-19. bioRxiv 2021 Jun 25. doi: 10.1101/2021.06.25.449893.
55.
Bye AP, Hoepel W, Mitchell JL, Jégouic S, Loureiro S, Sage T, Vidarsson G, Nouta J, Wuhrer M, de Taeye S, van Gils M, Kriek N, Cooper N, Jones I, den Dunnen J, Gibbins JM. Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a prothrombotic stimulus for platelets. Blood 2021; 138: 1481-1489.
56.
Nazy I, Jevtic SD, Moore JC, Huynh A, Smith JW, Kel- ton JG, Arnold DM. Platelet activating immune complexes identified in COVID-19 associated coagulopathy. medRxiv. 2020 Nov 4. doi: 10.1101/2020.11.04.20226076.
57.
Bastard P, Rosen LB, Zhang Q, Michailidis E, Hof- fmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 2020; 370: eabd4585. doi: 10.1126/science.abd4585.
58.
Pfister F, Vonbrunn E, Ries T, Jäck HM, Überla K, Lochnit G, Sheriff A, Herrmann M, Büttner-Herold M, Amann K, Daniel C. Complement activation in kidneys of patients with COVID-19. Front Immunol 2020; 11: 594849.
Share
RELATED ARTICLE
| eISSN: | 2300-6722 |
| ISSN: | 1899-1874 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
